Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.30 Analyst target: $1.00 Upside: 237.84%
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.